Tag: Immunotherapy
Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer
Real-world benefit seen with addition of bevacizumab to first-line chemotherapy for patients with high‐risk prognostic factors
Peanut Oral Immunotherapy Efficacious in Allergic Adults
Median tolerated dose increased from 30 mg to 3,000 mg of peanut protein at the exit challenge, equivalent to 12 peanuts
Outcomes With Immune Checkpoint Inhibitors Similar for Older, Younger Patients
Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
Neoadjuvant PD-1 blockade with dostarlimab enables nonoperative management strategy for large proportion of patients
Durable Disease Control Possible After Stopping Immune Checkpoint Inhibitors in NSCLC
Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration
AAAAI: Omalizumab Superior to Oral Immunotherapy in Multifood Allergy
Most patients include dietary consumption of allergy-triggering foods after gaining tolerance
Peanut Oral Immunotherapy Yields Higher Rates of Tolerance in High-Threshold Allergy
Significantly higher rates seen for desensitization, with durable response for home-measured peanut butter ingestion versus avoidance
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver Cancer
Clinically meaningful improvement seen in progression-free survival for transarterial chemoembolization plus lenvatinib and pembrolizumab
AI Can Reliably Predict Efficacy of Immune Checkpoint Inhibitor Therapy
SCORPIO machine learning system can predict certain outcomes across diverse cancer types and health care settings
Black Patients Have Similar Immune Checkpoint Inhibitor Effectiveness, Lower Toxicity
Black patients have longer time to treatment discontinuation, similar time to next treatment, slightly improved overall survival than White patients
